Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>Citi: CHINA LIFE 1Q25 NP Drastically Outruns Peers; TP $17.7
Recommend 14 Positive 24 Negative 5 |
||||
|
||||
|
Citi issued a research report on CHINA LIFE (02628.HK), of which 1Q25 results demonstrated modest growth in NBV on a like-for-like basis, strong profit growth, and decent BV expansion. China Life’s 1Q25 NBV grew 5% YoY on a like-for-like basis, lagging behind NCI (01336.HK)’s 68% growth on an actual basis, as well as CPIC (02601.HK), PING AN (02318.HK), and PICC GROUP (01339.HK), which recorded 39%, 35%, and 32% YoY growth, respectively, on a like-for-like basis, the broker added. China Life’s 1Q25 net profit surged 40% YoY, drastically outperforming other life peers, primarily due to reduced insurance service expenses amid lower medical claims and VFA contract fluctuations caused by rate hike. Citi set a target price of HKD17.7 for CHINA LIFE with a Buy rating. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
